Muscarinic Cholinergic Receptor Agonist and Peripheral Antagonist for Schizophrenia
In 5-week trial (n=182), combination of receptor agonist xanomeline and restricted muscarinic receptor antagonist trospium resulted in greater decrease in PANSS total score than placebo (mean difference, −11.6 points; p<0.001), but was linked to cholinergic & anticholinergic ADRs
Source:
New England Journal of Medicine